Related Experiment Video
Updated: Jan 24, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures
Luka Brcic1, Christian Kuchler2, Sylvia Eidenhammer2
1Diagnostic and Research Center for Molecular BioMedicine, Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria. luka.brcic@medunigraz.at.
Background:
Small cell lung cancer (SCLC) is usually diagnosed in the advanced stage. It has a very poor prognosis, with no advancements in therapy in the last few decades. A recent phase 1 clinical study, using an antibody-drug conjugate directed against DLL3, showed promising results. A prerequisite for this therapy is an immunohistochemical test for DLL3 expression. The antibody used in the clinical trial was bound to a specific platform, which is not available in all pathology laboratories. In this study, the expression of DLL3 was analyzed using different DLL3 antibodies in high-grade neuroendocrine tumors of the lung and cell cultures. Additionally, correlation of DLL3 expression with Rb1 loss and TP53 mutation was evaluated.
Methods:
The study cohort consisted of surgically resected cases, 24 SCLC and 29 large cell neuroendocrine carcinoma (LCNEC), from which tissue microarrays (TMAs) were constructed. The validation cohort included 46 SCLC samples, mostly small biopsies. Additionally, well-characterized SCLC cell lines were used. Immunohistochemical analysis was performed using four different DLL3 antibodies, as well as TP53 and Rb1 antibodies. Expression was evaluated microscopically and manually scored.
Results:
The comparison of all DLL3 antibodies showed poor results for the overall agreement, as well as positive and negative agreement. Differences were observed regardless of the applied cut-off values and the tumor type. The antibody used in the clinical trial was the only which always positively stained the tumor cells obtained from cell cultures with known DLL3 expression and was negative on cells that did not express DLL3. There was no correlation between p53 and DLL3 expression in SCLC and LCNEC. RB1 loss in SCLC showed statistical significant correlation with the DLL3 positivity (p = 0.037), while no correlation was found in LCNEC.
Conclusion:
The DLL3 antibody used in the clinical trial demonstrated superiority in the detection of DLL3 expression. Cell cultures, which can be used for DLL3 antibodies as positive and negative probes, were established. Evidence of DLL3 expression in high proportions of patients with LCNEC might provide basis for studies of new therapy options in this group of patients.
Insights
This study evaluated DLL3 antibodies for small cell lung cancer (SCLC) diagnostics. The clinical trial antibody showed superior performance, and RB1 loss correlated with DLL3 positivity in SCLC.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Small cell lung cancer (SCLC) has a poor prognosis with limited therapeutic advancements.
- DLL3-targeted antibody-drug conjugate therapy shows promise for SCLC.
- DLL3 immunohistochemistry is crucial for patient selection for this therapy.
Purpose of the Study:
- To assess the efficacy of different DLL3 antibodies for SCLC diagnosis.
- To evaluate DLL3 expression in high-grade neuroendocrine tumors.
- To correlate DLL3 expression with Rb1 loss and TP53 mutation.
Main Methods:
- Immunohistochemical analysis of 24 SCLC and 29 LCNEC cases using four DLL3 antibodies.
- Validation cohort included 46 SCLC samples and SCLC cell lines.
- Microscopic evaluation and manual scoring of DLL3, TP53, and Rb1 expression.
Main Results:
- Significant variability in agreement among DLL3 antibodies.
- The clinical trial antibody demonstrated superior specificity and sensitivity in cell cultures.
- RB1 loss correlated with DLL3 positivity in SCLC (p=0.037), but not in LCNEC.
Conclusions:
- The DLL3 antibody from the clinical trial is superior for detecting DLL3 expression.
- Cell cultures serve as reliable positive and negative controls for DLL3 antibody validation.
- DLL3 expression in LCNEC warrants further investigation for therapeutic strategies.
Related Concept Videos
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Types of Aggregate Grading
Well-graded aggregates include a complete range of necessary size fractions that fit together to create a dense matrix with minimal voids, represented by a smooth, continuous gradation curve. This type of grading ensures good...
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Lung Capacity
Sieve Analysis and Grading Curves
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...

